Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Simulations Plus, Inc. (NASDAQ: SLP) announced the renewal of FDA licenses for its DILIsym® software, a leading tool in predicting drug-induced liver injury (DILI). This one-year renewal allows FDA employees continued access to DILIsym across all divisions. Dr. Paul B. Watkins emphasized that this endorsement underscores DILIsym's value in assessing liver safety during drug development, especially after the FDA Modernization Act 2.0 signing. Dr. Brett A. Howell remarked on the growing importance of simulation technologies to enhance drug development efficiency amid rising healthcare costs. DILIsym's predictive modeling aids crucial decisions in drug development by identifying potential DILI risks and guiding go/no-go decisions. Simulations Plus has provided biosimulation solutions for over 25 years, employed by major stakeholders in the pharmaceutical industry.
Simulations Plus, a leader in pharmaceutical modeling software, reported Q2 fiscal 2023 revenues of $15.8 million, a 6% increase year-over-year. Software revenue rose 7% to $10.5 million, while services revenue saw a 4% increase to $5.3 million. Gross profit grew 10% to $13.1 million, achieving an impressive gross margin of 83%. However, net income decreased to $4.2 million with diluted EPS at $0.20, down from $4.4 million or $0.21 last year. Year-to-date, revenues climbed 2% to $27.7 million, with diluted EPS at $0.26, down from $0.36. The company maintains its full-year revenue guidance of $59.3 - $62.0 million and diluted EPS of $0.63 - $0.67.